好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

2018 Annual Meeting | C68 - Cognitive Impairment Due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment

Monday 04/23/18
07:00 AM - 09:00 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
David S. Knopman, MD, FAAN
Participants should be able to describe the continuum of cognitive function in the Alzheimer spectrum, understand the major and minor genetic influences on AD, describe the evolving biomarker diagnostic process for defining AD as a pathophysiology, and describe the appropriate indications for cholinesterase inhibitors and memantine.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Advanced Practice Provider
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic
Event Timeline
07:00 AM - 07:05 AM Luncheon Introduction
David S. Knopman, MD, FAAN
07:05 AM - 07:30 AM Speaker The Clinical Diagnosis of MCI and Dementia Due to AD
Richard J. Caselli, MD, FAAN
07:30 AM - 08:00 AM Speaker Biomarkers for the Etiological Diagnosis of AD
David S. Knopman, MD, FAAN
08:00 AM - 08:25 AM Speaker The Role for Genetics in AD Diagnosis and Management
Richard J. Caselli, MD, FAAN
08:25 AM - 08:45 AM Speaker Therapeutics in AD for 2018
David S. Knopman, MD, FAAN
08:45 AM - 09:00 AM Q&A Questions and Answers
Faculty Disclosures
David S. Knopman, MD, FAAN Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Richard J. Caselli, MD, FAAN The institution of Dr. Caselli has received research support from NIA. The institution of Dr. Caselli has received research support from State of Arizona.